Business Wire

Cyclic Materials Appoints Former Siemens and Alcoa CEO Klaus Kleinfeld to Board of Directors

20.5.2026 14:30:00 CEST | Business Wire | Press Release

Share

Cyclic Materials, the rare earth recycling company enabling domestic circular supply chain for critical materials around the world, today announced the appointment of Dr. Klaus Kleinfeld to its Board of Directors.

Dr. Kleinfeld brings decades of experience leading global industrial and advanced manufacturing businesses, including serving as CEO of two Fortune 500 companies – Siemens AG and Alcoa. His experience growing complex international operations, navigating global markets, and leading large industrial transformations will support Cyclic Materials’ industrial expansion to meet an accelerating global demand.

An internationally recognized executive, investor, and entrepreneur, Dr. Kleinfeld has advised multiple U.S. Presidents and global leaders on industrial competitiveness, technology, and economic development.

“Cyclic Materials is scaling a strategically vital solution that diversifies the global supply of critical materials,” said Dr. Kleinfeld. “Establishing resilient supply chains for rare earth elements is becoming increasingly essential to industrial competitiveness and advanced manufacturing. I look forward to actively supporting the company as it scales its technology and global operations.”

From 2008 to 2017, Dr. Kleinfeld served as Chairman and CEO of Alcoa and Arconic. Prior to that, he spent more than 20 years at Siemens, ultimately serving as CEO of Siemens AG until 2007. He currently serves as Chairman of KONUX and as a member of the supervisory boards of Brainlab, GreyOrange, and Fero Labs.

“Dr. Kleinfeld has operated at the scale and complexity Cyclic Materials is growing into,” said Ahmad Ghahreman, CEO and founder of Cyclic Materials. “His experience leading global industrial organizations, navigating geopolitical complexity, and scaling advanced manufacturing businesses will be highly valuable as we continue expanding our commercial footprint and creating a secure, resilient supply chain for rare earth materials.”

As demand for rare earth elements continues to accelerate and governments increasingly prioritize supply chain security, Cyclic is expanding its footprint globally to support a domestic supply of these critical materials across North America, Europe, and Asia.

Dr. Kleinfeld’s appointment reflects Cyclic Materials’ continued investment in strengthening its governance and industrial operating expertise as the company scales globally. This announcement follows Cyclic’s recent appointment of Roger Zakheim as Strategic Advisor. Mr. Zakheim currently serves as the Washington Director for the Ronald Reagan Presidential Foundation and Institute, and brings decades of experience in U.S. policy, including serving as General Counsel and Deputy Chief Staff Director of the U.S. House Armed Services Committee, as well as Deputy Assistant Secretary of Defense.

About Cyclic Materials
Cyclic Materials is building a resilient supply chain for rare earth elements (REEs) and other critical materials through the recycling of magnet-containing end-of-life products. Its innovative technology transforms end-of-life products into valuable raw materials that are essential to automotive, AI, robotics, defense, energy, medical, and other advanced manufacturing. With the success of its commercial demonstration and first shipments of high purity recycled Mixed Rare Earth Oxides (rMREO) to customers, the company is rapidly expanding its cutting-edge technology to commercial scale across North America, Europe and Asia, leveraging its proprietary MagCycle® and REEPure℠ processes to feed strategic industries with a secure supply of rare earths. The company was named Top 10 Climate Tech Companies to Watch by MIT Tech Review in 2025. Learn more at cyclicmaterials.earth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260520577161/en/

Contacts

Cyclic Materials Media Contact
Phil Sgro
cyclicmaterials@antennagroup.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye